A Consensus Parameter for the Evaluation and Management of Angioedema in the Emergency Department

Co-Chief Editors Joseph J. Moellman, MD, Jonathan A. Bernstein, MD, Christopher Lindsell, PhD

Workgroup Contributors (alphabetical) Aleena Banerji, MD, Paula J. Busse, MD, Carlos A. Camargo, Jr., MD, DrPH, Sean P. Collins, MD, MSc, Timothy J. Craig, DO, William R. Lumry, MD, Richard Nowak, MD, Jesse M. Pines, MD, MBA, MSCE, Ali S. Raja, MD, MBA, MPH, Marc Riedl, MD, Michael J. Ward, MD, MBA, Bruce L. Zuraw, MD

External Reviewers Deborah Diercks, MD, MSc, Brian Hiestand, MD, MPH, Ronna L. Campbell, MD, PhD, Sandra Schneider, MD, and Richard Sinert, DO

Abstract

Despite its relatively common occurrence and life-threatening potential, the management of angioedema in the emergency department (ED) is lacking in terms of a structured approach. It is paramount to...

From the Department of Emergency Medicine (JJM, CL) and the Department of Internal Medicine Division of Allergy and Immunology (JAB), University of Cincinnati College of Medicine, Cincinnati, OH; the Department of Medicine Division of Allergy and Immunology (AB) and the Department of Emergency Medicine (CAC), Massachusetts General Hospital, Boston, MA; the Department of Medicine and Clinical Immunology Mount Sinai Hospital (PJB), New York, NY; the Department of Emergency Medicine, Vanderbilt University (SPC, MJW), Nashville, TN; the Department of Internal Medicine and Pediatrics, Penn State Hershey Medical Center (TJC), Hershey, PA; Allergy and Asthma Specialists (WRL), Dallas, TX; the Department of Emergency Medicine, Henry Ford Health System (RN), Detroit, MI; the Department of Emergency Medicine, George Washington University (JMP), Washington, DC; the Department of Emergency Medicine, Brigham and Women’s Hospital (ASR), Boston, MA; the Department of Medicine, Section of Allergy and Immunology, David Geffen School of Medicine UCLA (MR), Los Angeles, CA; and the Department of Medicine, Section of Immunology, UC San Diego School of Medicine (BLZ), San Diego, CA.

Received September 22, 2013; revision received November 1, 2013; accepted November 6, 2013.

Supported by an unrestricted educational grant from CSL Behring, Dyax, Santarus, and Shire. No pharmaceutical company was involved in the planning or execution of the consensus process, and none had input to the development or approval of the consensus parameter. CSL Behring manufactures Berinert-P, Dyax manufactures Ecallantide, and Shire manufactures Icatibant. Each of these medications is approved only for the treatment of hereditary angioedema in the United States. Santarus is partnering with Pharming to distribute conestant-alpha, licensed as Rhucin in the United States, should it be approved by the Food and Drug Administration for the treatment of hereditary angioedema.

The University of Cincinnati provided support for travel and an honorarium to all authors who traveled to Cincinnati.

This manuscript has been endorsed by the American College of Allergy, Asthma & Immunology and the Society for Academic Emergency Medicine. Neither organization contributed to the planning or execution of the consensus process or the creation of the consensus parameter, but only reviewed the final document.

Dr. Banerji has financial ties to Shire, Dyax, CSL Behring, and Medscape. Dr. Bernstein has financial ties to CSL Behring, Dyax, Pharmming, Shire, and ViroPharma. Dr. Busse has financial ties to ViroPharma, CSL Behring, Dyax, and RMEI. Dr. Camargo is on the boards of Dey/Mylan and Sanofi-Aventis and has financial ties to Sanofi-Aventis. Dr. Collins has financial ties to Novartis, Trevena, Radiometer, BRAHMS, The Medicines Company, Cardiorentis, NIH/NHLBI, and Medtronic. Dr. Craig has financial ties to CSL Behring, Dyax, Viropharma, Shire, Pharming, Forrest, Genentech, Biota, Glaxo-Smith Klein, Grifols, Merck, Novartis, TEVA, and the Vietnam Education Foundation; has provided expert testimony on anaphylaxis; and is on the boards of AAAAAI, ACAAI, ALA-PA, and JCAAI. Dr. Lindsell has financial ties to Dyax. Dr. Lumry has financial ties to Viropharma, Dyax, Shire, CSL Behring, BioCryst, and Pharming. Dr. Moellman has financial ties to CSL Behring, Shire and Dyax. Dr. Riedl has financial ties to Dyax, Shire, ViroPharma, CSL Behring, BioCryst, Isis, Medscape, and RMEI. Dr. Zuraw has financial ties to CSL Behring, Shire, Dyax, BioCryst, Isis, Sanofi-Aventis, Novartis, Genetech, and the Robert Michael Educational Institute (RMEI). The other authors have no relevant financial information or potential conflicts of interest to disclose.

Supervising Editor: Joshua N. Goldstein, MD, PhD.

Address for correspondence and reprints: Joseph J. Moellman MD; e-mail: moellmjj@uc.edu, jmoellman@cinci.rr.com.
INTRODUCTION AND RATIONALE FOR DEVELOPMENT

Overview

Angioedema is a physical sign secondary to swelling of the subcutaneous or submucosal tissues and is due to enhanced vascular permeability, which allows movement of fluid from the vascular space into the interstitial space. Angioedema is non-pitting, non-gravity-dependent, and transient (lasting up to 7 days). It is critical to distinguish angioedema from edema, which is pitting, dependent, and persistent. Angioedema may be life-threatening, depending in large part on its underlying cause and body location. Thus, the clinical approach to a patient presenting in the emergency department (ED) with angioedema should include a consideration of potential causes. This article is meant to provide the emergency physician (EP) with a practical framework for classifying angioedema and to outline management based on this classification.

Most ED visits for angioedema will involve allergic or idiopathic angioedema, with or without concomitant urticaria or evidence of anaphylaxis. These forms of angioedema are typically mediated by histamine, and their management is usually familiar to ED staff. The key challenge in the management of angioedema in the ED, however, is recognizing and treating potential nonhistaminergic (bradykinin-mediated) angioedema. Unlike histamine-mediated angioedema, bradykinin-mediated angioedema is not associated with urticaria, does not respond to antihistamines or corticosteroids, and is poorly responsive to epinephrine. Bradykinin-mediated angioedema tends to be more severe, longer lasting, and much more likely to involve concurrent abdominal symptoms than histamine-mediated angioedema.

Epidemiology

When angioedema develops, it often leads to an urgent (unscheduled) office or ED visit. Population-based data are lacking, but it is likely that patients with new-onset or recurrent angioedema will go to the ED. Although anecdotal, this behavior fits that of pediatric patients with anaphylaxis; data suggest that roughly three-fourths of these children are managed in the ED.1

Few studies have examined the epidemiology of ED visits for angioedema. To date, all studies have relied on the International Classification of Diseases, 9th Edition, Clinical Modification (ICD-9-CM) code 995.1 to identify cases. Using this approach is limited, as the sensitivity and specificity of ICD-9-CM criteria to identify angioedema are currently unknown. Findings by Clark and Camargo,2 who demonstrated the low sensitivity and clinically relevant bias that comes from using ICD-9-CM anaphylaxis codes as the only source of case identification, further emphasize the need to overcome these methodologic issues to generate more accurate epidemiologic data on angioedema.

Based on data from the National Hospital Ambulatory Medical Care Survey (NHAMCS), there are as many as 80,000 to 112,000 ED visits for angioedema annually.3,4 The hospitalization rate for angioedema was 4.0 per 100,000 in 2005, making this condition the “dominant allergic disorder that results in hospitalization in the United States.”5 About 18% of ED visits coded as angioedema result in hospitalization.4 However, understanding the true epidemiology of angioedema is hampered by persistent confusion among clinicians about the case definition, and more specifically, the distinction between different groups of allergic reactions that might present to the ED including: 1) anaphylaxis with angioedema, 2) an isolated angioedema disorder, or 3) other related conditions such as chronic urticaria with angioedema. This consensus parameter focuses on the presentation of isolated angioedema disorders to the ED.

Angioedema disorders are the result of either bradykinin- or histamine-mediated responses.6 Many different factors are associated with the bradykinin-mediated angioedema disorders, most notably hereditary conditions and specific types induced by medication. Up to 50% of hereditary angioedema (HAE) patients in the United States experiencing attacks have been reported to require ED visits, with the majority of these patients requiring hospitalization.4 A chart review conducted at five academic EDs revealed that 30% of adult ED patients with angioedema had angiotensin-converting enzyme (ACE) inhibitor-induced angioedema, with 18% of these being admitted to observation units, 12% being admitted to inpatient units, and 11% being admitted to intensive care units (ICUs).7 Bluestein and colleagues8 also found that 30% of angioedema cases in the ED were induced by ACE inhibitors, although they noted a lower admission rate of 14% in their community setting. The possibility of medication-induced angioedema in children should also not be ignored. Although rare, in one study of 42 cases of pediatric angioedema, 7% (n = 3) presented with upper airway obstruction and were taking either an ACE inhibitor or a calcium channel blocker.9

distinguish the different etiologies of angioedema from one another and more specifically differentiate histaminergic-mediated angioedema from bradykinin-mediated angioedema, especially in lieu of the more novel treatments that have recently become available for bradykinin-mediated angioedema. With this background in mind, this consensus parameter for the evaluation and management of angioedema attempts to provide a working framework for emergency physicians (EPs) in approaching the patient with angioedema in terms of diagnosis and management in the ED. This consensus parameter was developed from a collaborative effort among a group of EPs and leading allergists with expertise in angioedema. After rigorous debate, review of the literature, and expert opinion, the following consensus guideline document was created. The document has been endorsed by the American College of Allergy, Asthma & Immunology (ACAAI) and the Society for Academic Emergency Medicine (SAEM).
Classification
It is difficult, if not sometimes impossible, to establish a precise cause of swelling in a patient presenting with angioedema in the ED. Therefore, it is recommended that patients be categorized using the following classification (Table 1): 1) anaphylaxis, 2) histaminergic angioedema without anaphylaxis (including both allergic and idiopathic angioedema), and 3) nonhistaminergic angioedema (including both HAE and ACE inhibitor–induced angioedema). Because the pathophysiology of these groups is different, the clinical manifestations and optimal treatments also differ. Unlike histamine-mediated angioedema, bradykinin-mediated angioedema does not respond to antihistamines or corticosteroids and is only poorly responsive to epinephrine. Bradykinin-mediated angioedema tends to be more severe, longer-lasting, and much more likely to involve the abdominal viscera than histamine-mediated angioedema.10

<table>
<thead>
<tr>
<th>Classification</th>
<th>Disease</th>
<th>Pathogenesis</th>
<th>Prevalence</th>
<th>Salient features</th>
<th>Risk of Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaphylaxis</td>
<td>Anaphylaxis</td>
<td>IgE-mediated with mast cell degranulation</td>
<td>Common</td>
<td>Preceded by exposure to relevant allergen (especially foods, stinging insects, and drugs); rapid development of symptoms, often including pruritic urticaria with the angioedema. Multisystem involvement, possibly including lower respiratory, circulatory, or gastrointestinal systems.</td>
<td>Yes</td>
</tr>
<tr>
<td>Histaminergic angioedema without anaphylaxis</td>
<td>Allergic angioedema</td>
<td>IgE-mediated with mast cell degranulation</td>
<td>Common</td>
<td>Preceded by exposure to relevant allergen (especially foods, stinging insects, and drugs); rapid development of symptoms, often including pruritic urticaria with the angioedema.</td>
<td>Variable</td>
</tr>
<tr>
<td></td>
<td>Idiopathic angioedema</td>
<td>Probably mast cell degranulation</td>
<td>Common</td>
<td>Recurrent swelling usually but not always associated with pruritic urticaria.</td>
<td>Very low</td>
</tr>
<tr>
<td></td>
<td>Drug-induced</td>
<td>Probably mast cell</td>
<td>Common</td>
<td>Often associated with exposure to aspirin/NSAIDs or drugs that cause nonspecific mast cell degranulation.</td>
<td>Variable</td>
</tr>
<tr>
<td>Nonhistaminergic angioedema</td>
<td>HAE due to C1-INH deficiency</td>
<td>C1-INH deficiency with bradykinin generation</td>
<td>Rare</td>
<td>Recurrent angioedema or abdominal pain without urticaria, may be associated with prodrome, symptoms usually begins before age 20 years, often positive family history with autosomal dominant inheritance.</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>HAE with normal C1-INH</td>
<td>Unknown, possibly with bradykinin generation</td>
<td>Rare</td>
<td>Recurrent angioedema without urticaria, often involves face and tongue, predominantly affects women, inherited in autosomal dominant pattern with low penetrance.</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Acquired C1-INH deficiency</td>
<td>C1-INH deficiency with bradykinin generation</td>
<td>Rare</td>
<td>Recurrent angioedema or abdominal pain without urticaria. Usually seen in individuals over the age of 40 years and often associated with an underlying disease, especially lymphoreticular disorder.</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>ACE inhibitor–induced</td>
<td>Prolonged half-life of bradykinin</td>
<td>Common</td>
<td>Should be suspected in any patient with angioedema who is taking an ACE inhibitor (or an ARB). African Americans and patients on immunosuppressives are at significantly enhanced risk. Can occur at anytime, even years after starting the ACE inhibitor.</td>
<td>Variable</td>
</tr>
<tr>
<td></td>
<td>Idiopathic</td>
<td>Unknown, possibly bradykinin</td>
<td>Rare</td>
<td>Resembles histaminergic idiopathic angioedema except that patients are nonresponsive to even high-dose antihistamines.</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; C1-INH = C1 inhibitor gene; HAE = hereditary angioedema; IgE = immunoglobulin E; NSAIDs = nonsteroidal anti-inflammatory drugs.
angioedema also frequently involves the upper airway, with a significant risk of death due to asphyxiation. Table 2 illustrates the general approach to classifying and managing angioedema in the ED. Details of the evaluation and management are expounded below.

Rationale for Development of a Parameter for ED Angioedema Management

The growing body of evidence describing the underlying mechanisms resulting in angioedema presenting to the ED provides the foundation necessary to care for these patients. Likewise, with the recent development and availability of novel pharmaceutical agents to treat bradykinin-mediated angioedema, it has become paramount that EPs be able to distinguish between histamine-mediated and bradykinin-mediated etiologies.

The Practice Parameter Developmental Process

In the following sections, we discuss recommendations for the evaluation, management, and follow-up of the angioedema patient presenting to the ED. These recommendations were developed collaboratively among a group of allergists and EPs with expertise in this area. This consensus parameter was developed following a rigorous process to maximize use of available evidence.

The workgroup included experts in the specialties of emergency medicine (EM) and allergy and immunology. The chairs (JJM, JAB) invited workgroup members to participate in the parameter development. The charge to the workgroup was to use a systematic literature review, in conjunction with consensus expert opinion and workgroup-identified supplementary documents, to develop practice parameters that provide a comprehensive approach for an assessment and management of angioedema in the ED. A search of the medical literature was performed for a variety of terms that were considered to be relevant to this practice parameter. Literature searches were performed on PubMed, Google Scholar, and the Cochrane Database of Systematic Reviews. All reference types were included in the results. References identified as being relevant were searched for further relevant sources, and those were searched. In addition, members of the workgroup were asked for references that may have been missed by this initial search. Published clinical studies were rated by category of evidence and used to establish the strength of the recommendations (Table 3). However, a formal evidence evaluation system such as the GRADE scheme was not used.

Each individual element of the recommendations was derived by an allergist–EP team pair. Elements were then combined into a parameter during an in-person conference. The approach taken was to generate a practical, evidence-based tool that could be used by EPs to guide their practice. The consensus parameter includes an executive summary of recommendations. Each recommendation is supported by a discussion of the literature. Finally, participants identified areas where lack of evidence suggests a role for future research, as well as possible barriers to implementation of the parameter. The parameter was appraised by external reviewers identified by the workgroup as experts in the field of EM and allergy and immunology. Based on this process, this parameter represents an evidence-based, broadly accepted consensus document.

EXECUTIVE SUMMARY

Angioedema can be classified as either bradykinin-mediated or histamine-mediated angioedema. Angioedema secondary to ACE inhibitors is a common side effect of this class of drugs and occurs when decreased metabolism of bradykinin leads to excess accumulation. HAE type I and type II are forms of angioedema due to a functionally abnormal C1-inhibitor (C1-INH) gene that

Table 2
Algorithmic Approach to the Management of Angioedema in the ED

<table>
<thead>
<tr>
<th>Step</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Employing a simple classification scheme for angioedema can help in developing an efficient and effective approach to assessing and managing patients presenting with angioedema. The first step in managing any patient in the ED is to sufficiently manage the airway and breathing, as well as to support circulatory function if necessary. Once the patient is stabilized, a focused history and physical should be obtained to separate bradykinin-mediated (ACE inhibitor–induced, HAE) from histamine-mediated. Subsequent distinctions between the underlying causes of angioedema can then be made to ensure appropriate longitudinal management and follow-up care. If the patient is on an ACE inhibitor, stop the medication and provide airway management support. If the patient has a known history of HAE, treat according to HAE guidelines using one of the recommended “on demand” therapies (Table 4). If the patient has signs of anaphylaxis (i.e., hypotension, vomiting, vasculature instability), administer epinephrine and treat according to anaphylaxis guidelines.</td>
</tr>
</tbody>
</table>

ACE = angiotensin-converting enzyme; HAE = hereditary angioedema.

Table 3
Classification of Recommendations and Evidence

<table>
<thead>
<tr>
<th>Category of evidence</th>
<th>Strength of recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ia. Evidence from meta-analysis of randomized controlled trials</td>
<td>A. Directly based on category I evidence</td>
</tr>
<tr>
<td>Ib. Evidence from at least one randomized controlled trial</td>
<td>B. Directly based on category II evidence or extrapolated recommendation from category I evidence</td>
</tr>
<tr>
<td>Iia. Evidence from at least one controlled study without randomization</td>
<td>C. Directly based on category III evidence or extrapolated recommendation from category I or II evidence</td>
</tr>
<tr>
<td>Iib. Evidence from at least one other type of quasi-experimental study</td>
<td>D. Directly based on category IV evidence or extrapolated recommendation from category I, II, or III evidence</td>
</tr>
<tr>
<td>III. Evidence from nonexperimental descriptive studies, such as comparative studies</td>
<td>E. Based on consensus of the Joint Task Force on Practice Parameters</td>
</tr>
<tr>
<td>IV. Evidence from expert committee reports or opinions or clinical experience of respected authorities or both</td>
<td>LB. Laboratory Based</td>
</tr>
</tbody>
</table>

Note: This table classifies recommendations based on the strength and quality of evidence supporting them.
results in the overproduction of bradykinin. HAE with normal C1-INH function with or without a genetic defect has been well-described, but to date only indirect anecdotal evidence supports bradykinin as the mediator. Acquired C1-INH deficiency clinically resembles HAE, but the low C1-INH is from consumption of the protein due to an underlying lymphoproliferative disorder and/or an antibody directed against C1-INH, resulting in the overproduction of bradykinin. Most idiopathic angioedema is thought to be histamine-mediated and is frequently responsive to H1 antagonists, epinephrine, and corticosteroids; however, refractory cases may be secondary to bradykinin. In patients with idiopathic angioedema unresponsive to H1 antagonists, epinephrine, and corticosteroids, without a family history of angioedema, in the absence of direct evidence for bradykinin as the primary mediator of swelling, it would be premature to recommend the use of therapies approved for HAE.

Different types of angioedema have various historical features that are helpful for determining the putative cause. The physical examination of the angioedema patient should focus initially on vital signs and proceed to a targeted, focused examination of the airway, integumentary, and abdominal regions. There are no point-of-care or laboratory-based tests available in the ED to provide immediate guidance on treatment to the EP. However, C4 and tryptase levels should be considered to assist in the diagnosis of HAE and angioedema associated with anaphylaxis, respectively. Results of these labs when drawn during an angioedema attack are particularly useful during follow-up with a primary care physician, allergist, or angioedema specialist and on return of the patient to the ED.

All patients with head and neck angioedema with any lingual involvement, as well as those with upper airway complaints, may benefit from flexible fiberoptic laryngoscopy, if immediately available, to determine the extent of involvement of the base of the tongue and the larynx. This is necessary to determine the possible need for airway management and the appropriate disposition of the patient. Radiographic techniques for assessment of the airway in patients presenting with acute angioedema have limited utility, and the unavoidable delay and reduced medical observation caused by these procedures may impose unnecessary risk. General monitoring of angioedema patients in the ED should be performed in a similar manner to the approach taken for patients with other respiratory or airway complaints, which includes close monitoring of oxygen saturation, cardiac status, and clinical signs and symptoms. Maneuvers such as supplemental oxygen, nasal trumpets, and bag–valve–mask ventilation may be useful temporizing measures for the angioedema patient with mild airway involvement, but are not a substitute for intubation if there is any concern about airway compromise. The decision to intubate or perform a more aggressive procedure should be based on the physician’s assessment of the patient’s prior history, airway anatomy, other comorbidities, and objective nasopharyngeal findings. When invasive airway management is indicated, maneuvers may involve the placement of an endotracheal tube, which requires patient sedation and analgesia to ameliorate significant discomfort. Once the decision to intubate is made, a rescue plan should be in place that involves having alternative airway devices available as rescue devices, as well as the means to perform a cricothyrotomy if necessary.

Treatment of angioedema depends on historical features of the patient and, if available, his or her preexisting diagnosis. If angioedema presents with signs of anaphylaxis (urticaria, asthma, hypotension), epinephrine is recommended. Standard treatment for histamine-mediated angioedema includes H1 and H2 antagonists and corticosteroids and may require epinephrine in life-threatening situations. While generally not effective for bradykinin-mediated angioedema, these treatments are not contraindicated, and if a putative cause of angioedema is unknown, epinephrine followed by H1 antagonists and corticosteroids should be given. The only potential acute treatment currently readily available for the treatment of ACE-induced or other bradykinin-mediated angioedema in the ED is fresh-frozen plasma (FFP), which has a risk of viral transmission, allergic reactions, and volume overload and a possibility of worsening symptoms in HAE. Several targeted therapies are now FDA-approved in the United States for the treatment of acute HAE attacks. These novel therapies, including icatibant, ecallantide, and C1-INH concentrate, are effective for the treatment of HAE attacks and may have benefit in ACE inhibitor–induced angioedema, but data are limited to support these treatments for non-HAE patients. There is a paucity of data to guide disposition decisions for hospitalization versus discharge home for angioedema patients. The Ishoo criteria provide one potential way for a physician to assess risk and admission decisions; however, these criteria have not yet been validated.

**ANGIOEDEMA: DEFINITIONS**

**Summary Statement 1:** Angioedema can be classified as either bradykinin-mediated or histamine-mediated angioedema. (LB) Histamine-mediated angioedema is often associated with urticaria and with swelling episodes that typically resolve within 24 to 48 hours. Causes include drugs, foods, latex, and insect stings. Bradykinin-mediated angioedema is not mediated by IgE antibodies and is not associated with urticaria. Swelling attacks in bradykinin-mediated angioedema typically last 2 to 5 days and are characteristically unresponsive to antihistamines and/or corticosteroids.6,13–15

**Summary Statement 2:** Angioedema secondary to ACE inhibitors is a common side effect of this class of drugs and occurs when decreased metabolism of bradykinin leads to excess accumulation. (LB) Angioedema is a well-known side effect associated with use of ACE inhibitors. About 0.1% to 0.7% of patients treated with these agents are estimated to develop angioedema, characterized mostly by edema of the lips and tongue.16,17 African Americans and patients on immunosuppressants tend to be at higher risk.18 The rate of development of angioedema has been shown to be the highest during the first 30 days of initiation of ACE inhibitors.
The mediator of angioedema is ACE inhibitor, the average time to the next angioedema attack is 10 months.20 The mediator of angioedema is bradykinin.

It is notable that other drugs affecting the renin-angiotensin system such as angiotensin receptor blockers and renin antagonists have been shown to cause angioedema, but secondary to a different unknown mechanism. Other non-histamine-mediated drug reactions include angioedema associated with inhibition of cyclooxygenase, leading to an accumulation of leukotriene mediators as seen with reactions to nonsteroidal anti-inflammatory drugs (NSAIDs).21 Patients with this condition usually manifest with urticaria and facial swelling upon exposure to the drug, but can present with swelling only.22

Summary Statement 3: HAE Type I and Type II are forms of angioedema due to a functionally abnormal C1-INH gene that results in the overproduction of bradykinin. (LB)

Hereditary angioedema is a rare form of angioedema that affects approximately 1 in 50,000 in the general population.23 Angioedema of this type usually begins in childhood or young adulthood and may worsen at puberty.24 Fifty percent of patients manifest recurrent episodes of swelling or abdominal pain by the age of 10 years.25 The underlying cause is a mutation of the gene encoding the C1-INH, which is inherited in an autosomal dominant pattern with relatively high penetrance. Two subtypes are recognized. Type I, which comprises 85% of cases, has low antigenic and functional C1-INH levels. Patients with normal or high antigenic C1-INH levels but abnormal C1-INH function are referred to as Type II.22,24,25 Type II HAE is caused by synthesis of a dysfunctional C1-INH protein.24,26 HAE due to C1-INH deficiency has been shown to be mediated by bradykinin.27 Many patients experience prodromal symptoms prior to an attack. A prominent prodromal symptom is erythema marginatum. This is an erythematous serpentine but nonpruritic and nonraised rash that should not be confused with urticaria.28

Summary Statement 4: HAE with normal C1-INH function with or without a genetic defect has been well-described, but to date only indirect anecdotal evidence supports bradykinin as the mediator. (C, LB)

Hereditary angioedema in patients with normal complement levels and normal C1-INH, but a well-defined family history of angioedema, is believed to be an autosomal dominant condition with low penetrance.17,29 Patients tend to present at a slightly older age compared to HAE due to C1-INH deficiency. It is reported more frequently in women, and attacks are characteristically more common in the facial region, especially tongue swelling. When affected, men tend to have less severe and less frequent attacks. Taking estrogen-containing therapies increases attack frequency in most patients.29,30 A minority of these patients has a mutation in the gene encoding coagulation factor XII, but the underlying cause of angioedema is unknown.17,30 Bradykinin is presumed to be the mediator of swelling in these patients, since most appear to respond to the same medications used to treat HAE with C1-INH deficiency but not to H1 antagonists, corticosteroids, or epinephrine.17,22

Summary Statement 5: Acquired C1-INH deficiency clinically resembles HAE but the low C1-INH is from consumption of the protein due to an underlying lymphoproliferative disorder and/or an antibody directed against C1-INH, resulting in the overproduction of bradykinin. (B, LB)

Acquired angioedema with C1-INH deficiency clinically resembles HAE due to C1-INH deficiency, but is not familial and tends to present in individuals over 40 years of age. Acquired C1-INH deficiency results from excessive C1-INH catabolism, which in approximately 15% of these cases is due to an underlying lymphoproliferative disorder and/or an autoantibody directed against C1-INH.17,31–33 The most common underlying disorders are lymphoreticular disorders (ranging from monoclonal gammopathy of unknown significance to lymphomas), but a variety of other malignancies and autoimmune disorders have been linked to the disease. In all cases, the mediator of swelling is bradykinin.

Summary Statement 6: Most idiopathic angioedema is thought to be histamine-mediated and is frequently responsive to H1 antagonists, epinephrine, and corticosteroids; however, refractory cases may be secondary to bradykinin. In patients with idiopathic angioedema unresponsive to H1 antagonists, epinephrine, and corticosteroids, without a family history of angioedema, in the absence of direct evidence for bradykinin as the primary mediator of swelling, it would be premature to recommend the use of therapies approved for HAE. (C)

Most patients with idiopathic angioedema are responsive to H1 antagonists, epinephrine, and corticosteroids; however, there is a small group of patients with idiopathic angioedema who do not respond to H1 antagonists, and refractory cases may be secondary to bradykinin. There is limited and weak evidence that the mediator of swelling is bradykinin in this small subset of patients.

EVALUATION: HISTORY

Figure 1 summarizes how elements of the history and physical examination should help to establish the working diagnosis.

Summary Statement 7: Different types of angioedema have various historical features that are helpful for determining the putative cause. (B)
Table 4 summarizes the historical characteristics of different types of angioedema. Although these characteristics do not directly distinguish one type of angioedema from another, they can help guide the EP toward the best possible treatment course.

**EVALUATION: PHYSICAL EXAMINATION**

**Summary Statement 8:** The physical examination of the angioedema patient should focus initially on vital signs and proceed to a targeted, focused examination of the airway, integumentary, and abdominal regions. (D)

**Vital Signs.** Although patients with either bradykinin- or histamine-mediated angioedema may have normal hemodynamic parameters, a number of patients may exhibit profound hypotension, tachycardia, and respiratory failure secondary to fluid shifts and airway edema. Due to vasodilation and increased vascular permeability, both bradykinin- and histamine-mediated angioedema have the potential to cause hypovolemic shock due to the shift of fluids in various bodily compartments. More importantly, asphyxiation secondary to airway edema is the leading cause of death in such patients, and thus it is essential to recognize subtle aspects of stridor and voice change in such patients immediately.12

**Head and Neck.** A focused, detailed oropharyngeal examination is essential in evaluating patients with either bradykinin- or histamine-mediated angioedema, specifically noting any edema in the lips, tongue, soft palate, or posterior pharynx since many treatment algorithms are determined by the specific region of the oropharynx affected. In particular, any presence of stridor or hoarseness must be noted because further diagnostic tests may be necessary, such as nasopharyngoscopy.12

Although oropharyngeal involvement can occur with either bradykinin- or histamine-mediated angioedema, it is more commonly seen in bradykinin-mediated angioedema. Over half of the patients with HAE have at least one episode of laryngeal edema during their lifetime. In the past, 30% of deaths in patients with HAE were due to laryngeal edema.11,34 In patients with ACE inhibitor–induced angioedema, the head and neck is the site most commonly affected.

**Integumentary.** The characteristic physical examination finding in bradykinin-mediated angioedema is a firm, nonpruritic swelling resulting from the accumulation of fluid in the reticular dermis and subcutaneous or submucosal tissue. The lesions are sometimes tender to palpation and are nonpitting. Histamine-mediated angioedema involves the deeper dermis and tends to be

---

Figure 1. Elements of the history and physical examination that help to establish the working diagnosis. FFP = fresh-frozen plasma; f/u = follow-up; HAE = hereditary angioedema.
more commonly associated with urticarial lesions that are discrete, pruritic erythematous papules in the epidermis that blanch with pressure. Both lesions arise from local vasodilatation and increased vascular permeability. Although it is uncommon to have urticarial lesions in bradykinin-mediated angioedema, some studies suggest that up to 50% of patients with histamine-mediated angioedema may present with both angioedema and urticarial lesions.22,35,36 In HAE, the most common sites of edema include the arms, legs, hands, and feet.22

**Abdomen.** Patients with bradykinin- or histamine-mediated angioedema may present with gastrointestinal symptoms. However, a patient presentation consistent with an “acute surgical abdomen” on examination, with severe tenderness, guarding, and rebound tenderness due to bowel wall edema, is much more characteristic of HAE patients. Cases of unnecessary abdominal surgery have been documented in HAE patients.22

**EVALUATION: ANCILLARY TESTING**

Summary Statement 9: There are no point-of-care or laboratory-based tests available in the ED to provide immediate guidance on treatment to the EP. However, C4 and tryptase levels should be considered to assist in the diagnosis of HAE and angioedema associated with anaphylaxis, respectively. Results of these labs when drawn during an angioedema attack are particularly useful during follow-up with a primary care physician or angioedema specialist or on return of the patient to the ED. (LB)

Almost all patients with HAE Types I and II have persistently low serum C4 levels; C4 is an excellent screening tool for C1-INH deficiency states.13,22,37 C4 levels combined with C1-INH level and C1-INH function (<50% using the chromogenic assay or <68% using the quidel assay) can be used to differentiate between Type I and Type II HAE and HAE that is not mediated by C1-INH deficiency.38 If C4 is normal during an attack in a patient not on androgens or C1-INH replacement, proceeding to C1-INH analysis is unnecessary.14 Currently, the C4 test is not recommended for patients younger than 1 year because of its unreliability in this age group. C1-INH and C4 concentrations increase to adult levels between 2 and 3 years of age.39 The chromogenic functional C1-INH assay appears to be superior to the ELISA-based (quidel) C1-INH functional assay.37

Serum tryptase levels are sometimes considered in differentiating various causes of angioedema. Tryptase is normal in HAE I and II and may be elevated in cases of anaphylaxis or other mast cell-mediated disorders manifesting with angioedema. An elevated tryptase level

---

**Table 4**

Historical Features of Patients Presenting with Different Causes of Angioedema

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>HAE</th>
<th>Acquired</th>
<th>ACE inhibitor-induced</th>
<th>Allergic</th>
<th>Idiopathic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age of onset</td>
<td>2–13 yr</td>
<td>Adult</td>
<td>Adult</td>
<td>Any age</td>
<td>Any age</td>
</tr>
<tr>
<td>Family history</td>
<td>75%</td>
<td>None</td>
<td>No</td>
<td>History of atopy</td>
<td>No</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>None</td>
<td>No*</td>
<td>No</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>Sex-associated predilection</td>
<td>Peripher arterial, facial, laryngeal, genitourinary</td>
<td>Peripheral arterial, facial, laryngeal, genitourinary</td>
<td>Lips, tongue, facial</td>
<td>Lips, tongue, laryngeal</td>
<td>Lips, tongue, rarely laryngeal</td>
</tr>
<tr>
<td>Location of attacks</td>
<td>Gradual over a few hours</td>
<td>Gradual over a few hours</td>
<td>Gradual over a few hours</td>
<td>Immediate within 1 hour</td>
<td>Variable</td>
</tr>
<tr>
<td>Speed of attack onset</td>
<td>3–5 days without treatment</td>
<td>Yes</td>
<td>No, if drug discontinued; attacks can persist for 4–6 weeks after drug discontinued</td>
<td>Yes only if reexposed to allergen avoided</td>
<td>Variable</td>
</tr>
<tr>
<td>Duration of attacks</td>
<td>Yes with or without treatment</td>
<td>Yes</td>
<td>No</td>
<td>Yes or no</td>
<td>Typically no but possible</td>
</tr>
<tr>
<td>Recurrent nature of attacks</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Associated with urticaria</td>
<td>Yes</td>
<td>Yes</td>
<td>Usually not</td>
<td>Yes</td>
<td>Variable</td>
</tr>
<tr>
<td>Presents with abdominal pain</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Response to H1 antagonists and oral corticosteroids</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Variable</td>
</tr>
<tr>
<td>Response to epinephrine</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Variable</td>
</tr>
</tbody>
</table>

Female >> Male.

ACE = angiotensin-converting enzyme; HAE = hereditary angioedema.

*For hereditary angioedema with normal complement with or without a genetic mutation.

† Can have a rapid onset in less than 1 hour.
can be helpful in ruling out HAE although a normal tryptase level provides no discriminatory information.

Laboratory testing is of little use to the ED evaluation and management of the patient with angioedema. Measurement of C4 and tryptase levels to discriminate between bradykinin- and histamine-mediated angioedema, respectively, typically takes longer to process and provide results than the time frame in which management decisions must be made in the ED. By the time testing is complete, it is known whether or not the patient has responded to H1 antagonists, corticosteroids, and epinephrine, and thus the likely mechanism for the attack can be surmised. Laboratory testing at the time of an attack, however, can be useful for the long-term management of patients with angioedema. For example, in 2% to 4% of cases of HAE, the C4 level is normal in between attacks but is low in virtually 100% during acute angioedema attacks, and in these patients subsequent measurements of the antigenic and functional C1-INH level are helpful to evaluate for HAE Type I versus Type II.22,37,38

Measuring the C4 level is an effective screening test to rule out HAE Type I and Type II, and initiating this in the ED will ensure that the patient has results available during follow-up and subsequent ED visits.22 It is not useful to screen with a CH50 or C3 complement level.38 It is prudent to obtain a C4 level in a patient with angioedema when no obvious etiology is found, especially if the angioedema appears to be mediated by bradykinin.39 It is important that C4 is sent to the laboratory in a timely fashion, as degradation and artificially low C4 levels may be reported if there is a significant delay in transfer or poor handling.37

Summary Statement 10: All patients with head and neck angioedema with any lingual involvement, as well as those with upper airway complaints, may benefit from flexible fiberoptic laryngoscopy, if immediately available, to determine the extent of involvement of the base of the tongue and the larynx. This is necessary to determine the possible need for airway management and the appropriate disposition of the patient. (C)

In the perioral region and neck, angioedema can involve any number of mucosal sites from the lips to the larynx, and the involvement of these sites is random and can be noncontiguous.12,40-46 Angioedema of the upper aerodigestive tract can be life-threatening if it causes airway compromise that is not recognized and treated. A major question for EPs is how and in whom to evaluate the airway beyond what can be seen on physical examination.12,40-46 Current studies are of small sample size but suggest that any presentation of head and neck angioedema can have associated swelling of the larynx, base of the tongue, or both. We recommend that those patients with involvement of the tongue, soft palate, or floor of the mouth should have direct visualization, if immediately available, of the base of tongue and airway. Patients who do show involvement of these deeper structures may require airway intervention, or at least close monitoring in an ICU with repeat laryngoscopy, depending on any changes in symptoms. Patients without involvement of these deeper structures may be medically treated, observed for a number of hours to document resolution of the swelling, and then discharged home.12,40-46 If nasopharyngoscopy is not immediately available to the EP, then the clinical assessment should consider stridor, hoarseness, drooling, and swelling as potential signs of airway involvement.

Summary Statement 11: Radiographic techniques for assessment of the airway in patients presenting with acute angioedema have limited utility, and the unavoidable delay and reduced medical observation caused by these procedures may impose unnecessary risk. (C)

There is very little in the medical literature regarding the use of neck radiographs or computed tomography (CT) imaging to help determine the extent of airway involvement in a patient presenting with acute angioedema. The use of radiography has most value in ruling out certain disease processes that may mimic angioedema, such as an abdominal CT scan in the patient with acute abdominal pain. The use of laryngeal ultrasonography may prove beneficial as a noninvasive tool to assess airway involvement, yet no studies to date have explored its feasibility or utility.

TREATMENT: ACUTE AIRWAY MANAGEMENT

Summary Statement 12: General monitoring of angioedema patients in the ED should be performed in a similar manner to the approach taken for patients with other respiratory or airway complaints, which includes close monitoring of oxygen saturation, cardiac status, and clinical signs and symptoms. (D)

The approach to monitoring patients with angioedema is similar to the course taken with other ED patients with either respiratory or airway complaints. Every patient should be placed on a pulse oximeter and a cardiac monitor. Pulse oximetry is useful to determine initial oxygenation during the primary assessment. Equally important, the physician can follow pulse oximetry to note trends with time and therapy. Unfortunately, pulse oximetry may be a late marker of airway issues and may not be abnormal until there is significant upper airway edema, at which point the patient could already be in significant respiratory distress. In general, even if pulse oximetry is in the normal range for the patient, it should not be the primary factor in the decision to intubate if there is concern about significant upper airway compromise. Similarly, cardiac monitoring is helpful to determine if there are other causes of the patient’s complaints, such as an arrhythmia or cardiac ischemia, or after potential cardiac-stimulatory medications (epinephrine) have been given. As with pulse oximetry, trends in cardiac monitoring may give an indication of whether the patient’s situation is worsening or whether initial therapy is helping.

Capnography is a useful adjunct to monitor a patient’s respiratory status and is a more sensitive indicator of ventilation difficulties than pulse oximetry. However, similar to pulse oximetry, patients with impending upper airway obstruction often have normal capnography despite heading toward airway
compromise. Capnography can be useful in two other scenarios associated with angioedema: 1) monitoring the adequacy of ventilation after intubation and 2) monitoring the level of sedation associated with other medications that may have been used for diagnostic (benzodiazepines/ketamine to facilitate nasopharyngoscopy) or therapeutic (H1 antagonists in the initial management of undifferentiated upper airway difficulties) purposes.

Summary Statement 13: Maneuvers such as supplemental oxygen, nasal trumpets, and bag–valve–mask ventilation may be useful temporizing measures for the angioedema patient with mild airway involvement, but are not a substitute for intubation if there is any concern about airway compromise. (D)

Supplemental oxygen may be considered for patients with airway or respiratory complaints and should be applied to those who are hypoxic. Nasopharyngeal airway devices (i.e., nasal trumpets) may act as temporizing measures and may assist with bag–valve–mask ventilation. While bag–valve–mask ventilation may temporarily be able to overcome the airway obstruction, as the disease progresses to significant laryngeal involvement, bag–valve–mask ventilation will become very difficult. Noninvasive ventilation, such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP), may act as a temporary measure to assist with ventilation in patients with hypercarbia. However, positive pressure ventilation does not aid in stenting open the airway for a prolonged period of time and is not definitive therapy.

Summary Statement 14: The decision to intubate or perform a more aggressive procedure should be based on the physician’s assessment of the patient’s prior history, airway anatomy, other comorbidities, and objective nasopharyngeal findings. (D)

The decision to intubate can be based on two broad approaches: 1) clinical gestalt and 2) objective evaluation. Clinical gestalt accounts for a patient’s prior history, such as previous rapid progression to intubation, difficult airway anatomy, or concomitant comorbidities that may affect the need for and ease of intubation such as underlying cardiorespiratory disease. The objective evaluation combines physical examination with nasopharyngoscopy findings. Findings such as a change in the patient’s voice, hoarseness, and stridor should raise the suspicion for significant airway involvement and the need for a definitive airway. Further, examination of the oropharynx is also important to differentiate those with primarily lip and anterior tongue swelling from others. An objective evaluation may provide more specific information about where the edema is occurring or how extensive the progression is.

Because of the importance of differentiating upper and lower airway involvement, in patients with throat or voice complaints, it may be prudent to obtain direct visualization of lower airway structures. Visualizing epiglottic, aryepiglottic, or laryngeal edema should raise concern for the need to secure the airway sooner than later. There are several methods to facilitate this evaluation, including an awake intubation or nasopharyngoscopy. Both of these approaches are discussed below. Tongue involvement should heighten one’s suspicion of possible airway concerns, while pharyngeal or laryngeal involvement definitely warrant close monitoring and consideration of early invasive airway management.

Summary Statement 15: When invasive airway management is indicated, maneuvers may involve the placement of an endotracheal tube, which requires patient sedation and analgesia to ameliorate significant discomfort. Once the decision to intubate is made, a rescue plan should be in place that involves having alternative airway devices available as rescue devices, as well as the means to perform a cricothyrotomy if necessary. (C)

Choice of Invasive Maneuvers. Extraglottic and supraglottic devices have become common rescue devices for use in the prehospital setting, the operating room, and the ED. In many cases, they have also superseded endotracheal intubation as the primary method of choice for securing a patient’s airway. However, they are not appropriate for patients with angioedema. Since a high proportion of patients with lingual and laryngeal involvement require intubation, there is a high likelihood that an extraglottic device will remain above the airway obstruction. While some extraglottic devices allow for blind passage of an endotracheal tube through them, there is only a slim chance that a blindly passed tube will be able to thread between the edematous tissues present in angioedema. In fact, the trauma caused by the tube if it fails to pass may precipitate worsening symptoms. In patients with angioedema who require airway management, endotracheal intubation is the procedure of choice.

Induction Agents. If a patient is not predicted to have a difficult airway and laryngoscopy is to be performed, standard induction and paralytic agents should be chosen. Etomidate is frequently used in the ED management of patients requiring intubation at a dose of 0.3 mg/kg IV. Etomidate is widely available, has a rapid onset time, and is appropriate for use in patients with angioedema. If available, ketamine may be a preferable agent. Induction doses of ketamine, typically 1.5 mg/kg IV, do not preserve airway reflexes. However, lower doses, typically below 1 mg/kg, may preserve a patient’s abilities to maintain his or her own airway and be appropriate for awake intubation. Midazolam is slower in onset, but can serve as an induction agent when etomidate and ketamine are not available.

Paralytics. Paralytics should be used with caution in patients with angioedema. Once given, the patient will be unable to respire on his or her own, and the full responsibility of maintaining oxygenation and ventilation falls on the clinician. If the clinician is unable to intubate and the angioedema prevents effective bag–valve–mask ventilation, a cricothyrotomy may be required. Succinylcholine is the most commonly used paralytic agent for intubation in the ED, having rapid onset at a dose of 1.5 mg/kg IV. Succinylcholine is
contraindicated in the presence of burns, denervating diseases, crush injuries, myopathies, and other risk factors for succinylcholine-induced hyperkalemia. If these comorbidities are present, nondepolarizing neuromuscular blocking agents such as rocuronium (1.0 mg/kg) and vecuronium (0.01 mg/kg) are appropriate alternatives.

**Intubation Methods.** The decision of how best to intubate a patient with angioedema should be made based on the patient’s prior history of disease severity and any direct airway visualization. If the patient has difficult airway predictors, a history of having a difficult airway, or angioedema so severe that the airway cannot be directly visualized, rapid sequence intubation with paralysis should not be attempted. Awake intubation using either video laryngoscopy or fiberoptic nasotracheal intubation should be performed. This allows for airway management without the removal of a patient’s airway reflexes until the endotracheal tube has passed through the vocal cords.

For awake intubation, local anesthesia should first be used, including atomized or topical nasal vasoconstrictors and anesthetic agents, followed by a drying agent such as glycopyrrolate (0.4 to 0.8 mg IV) to decrease saliva secretion and facilitate visualization. After sedation, the intubation can be performed. Nasotracheal intubation should never be performed blindly in the patient with angioedema, as airway distortion makes passage of the endotracheal tube extremely unlikely, and localized trauma may induce further swelling. However, a fiberoptic nasopharyngeal scope or bronchoscope, if available, may be used to directly visualize passage of the tube. The endotracheal tube should be preloaded onto the scope and then the scope passed through the nose. Similarly, video laryngoscopy can be used in patients who are only partially sedated. Additional sedation and a paralytic agent can be administered as soon as the airway is secured.

In patients without a difficult airway, video laryngoscopy still allows for better intubating conditions than direct laryngoscopy, resulting in faster times to intubation and an improved first-pass success rate. A direct laryngoscope may be used with awake laryngoscopy, if needed, or may be used to intubate the patient directly via rapid sequence with both a full-dose induction agent and a paralytic if a difficult airway is not predicted.

Patients with angioedema may have such severe edema that passage of an endotracheal tube through the glottis is impossible, even with advanced fiberoptic or video techniques. In these cases, a cricothyrotomy will be required. In those patients in whom this is anticipated to be a possibility, the location of the cricothyroid membrane should be marked prior to any airway intervention being attempted and, ideally, local anesthetic preinjected with the cricothyrotomy kit opened as a “double setup” in case it is needed emergently.

**TREATMENT: ACUTE PHARMACOLOGY**

**Summary Statement 16:** Treatment of angioedema depends on historical features of the patient and, if available, his or her preexisting diagnosis. (C) If angioedema presents with signs of anaphylaxis, epinephrine is recommended. Standard treatment for histamine-mediated angioedema includes H1 and H2 antagonists and corticosteroids and may require epinephrine in life-threatening situations. (A) While generally not effective for bradykinin-mediated angioedema, these treatments are not contraindicated, and if the putative cause of angioedema is unknown, epinephrine followed by H1 antagonists and corticosteroids should be given. (C) If the cause of angioedema is not apparent, initial standard treatment of angioedema should include epinephrine, H1 and H2 antagonists, and oral corticosteroids. If the patient manifests other organ system involvement (wheezing, shortness of breath, chest tightness), urticaria, or drop in blood pressure consistent with anaphylaxis, epinephrine should be administered. Epinephrine and oxygen are the most important therapeutic agents administered in anaphylaxis. Although there are no direct data to demonstrate that antihistamines mitigate any noncutaneous symptoms, theoretical benefit is possible. Appropriate volume replacement, either with colloid or with crystalloids, is essential for patients who are clinically unstable or refractory to initial therapy.

Epinephrine is the drug of first choice for life-threatening histamine-mediated angioedema, in particular when there is airway swelling or hypotension. It is not contraindicated in bradykinin-mediated angioedema but may have minimal benefit for severe upper airway swelling until other drugs and intubation are available. Epinephrine is not indicated for non-life-threatening angioedema not involving the airway. Epinephrine (0.01 mg/kg of a 1:1000 solution to a maximum of 0.5 mg) is best given intramuscularly for rapid absorption; IV administration should be avoided except in an emergency or code-type resuscitation. Duration of action is short, so repeat dosing may be required if symptoms persist or return. Adverse effects are short-lived and include increased heart rate, tremor, and anxiety. Use should not be withheld if indicated despite heart disease or other cardiovascular diseases.

H1 antagonists are the treatment of choice to suppress histamine-mediated angioedema, although they have no benefit in bradykinin-mediated angioedema. Because H1 antagonists are well-tolerated with minimal adverse effects, other than sedation, they should be administered in the absence of a clear history of HAE or ACE inhibitor–induced angioedema. In older adults, side effects can include delirium, urinary retention, constipation, and effects on ocular pressure. For time-critical therapy, IV diphenhydramine is the preferred agent. Doses vary by specific agents. The benefit is limited in anaphylaxis and in airway swelling; H1 antagonists should never be used in place of epinephrine for these two emergencies. Low-dose or nonsedating agents are preferred if time is not critical. H2 blockers, added to H1 antagonists, may be considered to prevent hypotension and urticaria associated with pruritus secondary to histamine. There are limited data to support the use of H2 blockers for allergic emergencies associated with angioedema in the acute setting.
Corticosteroids are effective for histamine-mediated angioedema. They have little to no benefit in bradykinin-mediated angioedema. Their action depends on suppression and activation of many proteins and peptides, and onset can take hours to days. They should not be used as a substitute for epinephrine for this reason. Adverse effects limit long-term use, but for acute therapy the adverse effects are considered acceptable. Dosing is specific to the agent. For IV therapy, 60 to 120 mg of methylprednisolone is commonly used, but randomized studies in angioedema are lacking. In those with allergy to other corticosteroids, dexamethasone is the preferred agent.

Summary Statement 17: The only potential acute treatment readily available for the treatment of ACE-induced or other bradykinin-mediated angioedema in the ED is FFP, which has a risk of viral transmission, allergic reactions, and volume overload and a possibility of worsening symptoms in HAE. (B)

Fresh-frozen plasma, which contains variable amounts of C1-INH, may be used for volume replacement in patients failing initial therapy. It tends to be readily available and inexpensive and is effective in most cases. There is a possibility of a hypersensitivity reaction to FFP. Worsening of an HAE attack has been described when FFP is given, but this has not been documented in the literature for ACE inhibitor-induced disease. The worsening of an HAE attack is believed to be due to providing additional substrate that may potentially worsen attack symptoms. This is primarily of concern only when the angioedema involves the airway. However, other investigators have reported this phenomenon with FFP to be rare.

Patients with a history of HAE may be taking antifibrinolytics and anabolic androgens for prophylaxis at the time of attack. Neither have an onset of action fast enough to be effective for treatment of an attack, although many patients will report taking “extra” androgen doses when an attack begins. Neither antifibrinolytics nor androgens will interfere with effectiveness of therapies for HAE. However, knowledge that antifibrinolytics and androgens may be prescribed to and used by this population helps identify these patients as possibly having HAE.

Analgesics and antiemetics should be prescribed as needed to alleviate the pain and nausea frequently manifested by HAE patients presenting with an acute abdominal attack. In mild HAE attacks, analgesics and antiemetics may be all that is needed; however, use of targeted therapies may mitigate the need for narcotics and result in more rapid resolution of the pain.

Summary Statement 18: Several targeted therapies are now FDA-approved in the United States for the treatment of acute HAE attacks. (A) These novel therapies, including icatibant, ecallantide, and C1-INH concentrate, are effective for the treatment of HAE attacks and may have benefit in ACE inhibitor-induced angioedema, but data are limited to support these treatments for non-HAE patients. (C)

Bradykinin-mediated angioedema resulting from dysregulation of the kallikrein–bradykinin pathway is distinct from allergic or histamine-mediated angioedema. Because bradykinin-mediated angioedema is generally unresponsive to H1 antagonists, corticosteroids, and epinephrine, five medications targeted at the underlying pathophysiology have been developed: two purified C1-INH protein concentrates derived from pooled donor plasma, a recombinant C1-INH protein product, a kallikrein inhibitor (ecallantide), and a bradykinin 2-receptor antagonist (icatibant). Of these, three are FDA-approved for attacks of HAE: ecallantide, icatibant, and one of the purified C1-INH protein concentrates. Table 5 summarizes these agents, their mechanisms of action, dosing, and side effects.

Human plasma-derived C1-INH concentrate (Berinert, CSL Behring, Marburg, Germany) administration provides the native plasma protein with numerous benefits, but it may result in more rapid resolution of pain.

Table 5
Targeted Therapies for Treatment of Acute HAE Attacks

<table>
<thead>
<tr>
<th>Medication</th>
<th>Trade Name</th>
<th>Dose</th>
<th>Route</th>
<th>Common Side Effects</th>
<th>Potential Serious Side Effects</th>
<th>Mechanism of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma-derived C1-INH</td>
<td>Berinert or Cinryze (off label in the USA)</td>
<td>20 units/kg or 1,000 units for Cinryze</td>
<td>IV</td>
<td>Dysgeusia</td>
<td>Hypersensitivity reactions, thrombosis, blood-borne infectious risk</td>
<td>C1-INH protein replacement</td>
</tr>
<tr>
<td>Ecallantide</td>
<td>Kalbitor</td>
<td>30 mg</td>
<td>SQ</td>
<td>Headache, nausea, pyrexia, injection site reactions</td>
<td>Hypersensitivity reactions</td>
<td>Plasma-kallikrein inhibitor</td>
</tr>
<tr>
<td>Icatibant</td>
<td>Firazyr</td>
<td>30 mg</td>
<td>SQ</td>
<td>Injection reactions, pyrexia, increased transaminases, dizziness</td>
<td>None reported</td>
<td>Bradykinin 2-receptor antagonist</td>
</tr>
<tr>
<td>Recombinant C1-INH*</td>
<td>Ruconest</td>
<td>50 units/kg</td>
<td>IV</td>
<td>Sinusitis, rash, pruritus</td>
<td>Hypersensitivity reactions</td>
<td>C1-INH protein replacement</td>
</tr>
</tbody>
</table>

C1-INH = C1-inhibitor; HAE = hereditary angioedema; IV = intravenous; SQ = subcutaneous.

*Currently not FDA-approved, but licensed in Europe.
physiologic inhibitory functions, including regulation of Factor XII and kallikrein activity, thereby reducing bradykinin production in the setting of C1-INH deficiency. C1-INH protein concentrate is FDA-approved for the treatment of acute abdominal, facial, or laryngeal attacks of HAE in adult and adolescent patients, at a dose of 20 U/kg, given IV.\(^5\) This dose is apparently appropriate in children even though it is off label in patients below 12 years of age.\(^5\) Another plasma-derived C1 inhibitor, Cinryze (Viropharma, Exton, PA), can also be used off label for HAE attacks in the United States and is approved for the treatment of HAE in adults in the European Union at 1,000 units IV. Recombinant human C1-INH (Ruconest) replaces C1-INH protein activity. It is currently investigational in the United States, but is licensed in Europe for the treatment of HAE attacks in adults (see Table 5).\(^5\)

Ecallantide (Kalbitor) is a highly specific plasma kallikrein inhibitor targeted at reducing kallikrein-mediated production of bradykinin. This product is FDA-approved for the treatment of acute HAE attacks in patients 16 years and older and is administered by three subcutaneous injections (each injection 1 mL or 10 mg) for a total dose of 30 mg.\(^5\) Due to a risk of anaphylaxis, which was observed in approximately 3% of study participants, ecallantide should be administered under the direct supervision of a health care professional capable of treating hypersensitivity reactions.\(^37\) Because the majority of the anaphylaxis reactions occurred within 1 hour of use, observation of the patient for at least 60 minutes or greater following use of ecallantide is recommended.

Icatibant (Firazyr) is a synthetic decapeptide and selective bradykinin-2 receptor antagonist that blocks the vascular effects of bradykinin. FDA-approved for physician- or patient-administered treatment of HAE attacks in adults 18 years and older, it is administered by single subcutaneous injection at a dose of 30 mg.\(^5\) Pain and erythema at the injection site occurs in the majority (97%) of patients, but this side effect is considered relatively benign and temporary. As with ecallantide and C1-INH, a second, and rarely a third, dose of icatibant may be necessary.

No randomized comparative studies of the targeted therapies have been conducted, and both trial design and efficacy end points have differed among the studies. Differences also exist among agents with regard to safety concerns and route of administration. Clinical studies of HAE-specific agents have also demonstrated that a small subset of HAE attacks (~10%) require a second dose of medication due to a partial response or recurrence of symptoms.

Studies examining the efficacy of these agents in ACE inhibitor and acquired angioedema are ongoing.\(^5\) Their use in idiopathic angioedema refractory to histamine-targeted treatment has not been studied.

### Disposition

Summary Statement 19: There is a paucity of data to guide disposition decisions for hospitalization versus discharge home for angioedema patients. The Ishoo criteria provide one potential way for a physician to assess risk and admission decisions; however, these criteria have not yet been validated. (C)

**Risk Stratification.** Patient disposition for hospital admission or discharge home should be determined according to the severity of airway involvement. The Ishoo classification includes principles that can be applied to various bradykinin-mediated angioedema disorders.\(^12\) While this tool does assist the treating physician with information to aid in risk stratification, it was derived retrospectively, has yet to be validated, and requires the use of laryngoscopy to stage a patient (Table 6).

Patients in classification stages I and II with only face, lip, or soft palate edema can often be managed as outpatients or admitted to an extended monitoring location (inpatient ward or observation unit). This is because patients at Ishoo stage I or II, and patients with a normal-appearing larynx on nasopharyngoscopy, rarely progress to the need for airway intervention.\(^61\) When the angioedema involves more than three physical sites from among lips, anterior tongue, floor of mouth, soft palate, base of tongue, and larynx, there is increased risk of airway involvement, and therefore outpatient management is not recommended.\(^43\) Generally, all patients with respiratory distress or in need of airway intervention should be admitted to the ICU; patients in stages III and IV should be cared for in the ICU.

**Role of Observation Units.** Patients with mild to moderate angioedema who are admitted to the inpatient ward can frequently be discharged home within 24 hours.\(^12\) This opens the possibility of using ED-based observation units. Although not rigorously studied for use in angioedema, some centers have implemented angioedema protocols in ED-based observation units, and standardized diagnostic and therapeutic protocols with inclusion/exclusion criteria and disposition decision aids already exist (http://www.emergencykt.com/).

**Consultation in the ED.** Consultation with an otolaryngologist should be considered regarding decisions on airway management if time permits. Consultation with an allergist/immunologist for the treatment of ED patients with acute and/or recurrent angioedema is unlikely to change the emergent or acute therapeutic course and airway management. However, consultation may guide the EP in obtaining useful laboratory testing during the time of an attack and for ensuring that appropriate follow-up is arranged. Patients with HAE

<table>
<thead>
<tr>
<th>Stage</th>
<th>Clinical Findings</th>
<th>Disposition</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Facial rash, facial edema, lip edema</td>
<td>Home or admission</td>
</tr>
<tr>
<td>II</td>
<td>Soft palate edema</td>
<td>Home or admission</td>
</tr>
<tr>
<td>III</td>
<td>Lingual edema</td>
<td>Intensive care unit</td>
</tr>
<tr>
<td>IV</td>
<td>Laryngeal edema</td>
<td>Intensive care unit</td>
</tr>
</tbody>
</table>

**Table 6: Ishoo Classification\(^12\) for Monitoring Severity of the Upper Airway**
presenting with angioedema may have targeted therapy available, and consultation with their HAE specialist, which is most often an allergist/immunologist, could guide the use of targeted therapies.

Follow-up. A well-formulated plan with follow-up to an appropriate provider can avoid an admission for the patient with mild to moderate angioedema whom the treating clinician is comfortable discharging home. Testing performed in the ED, particularly C4 and tryptase levels, can be evaluated during the follow-up visit. HAE patients should have a specialist familiar with the disease involved in their care.52,62 When it is a patient’s first episode of angioedema, the attack is unresponsive to H1 antagonists and corticosteroids, and the patient carries a family history of attacks, it is important to arrange follow-up with an allergist/immunologist or HAE specialist. This will ensure that the patient is educated on HAE triggers, including medications such as estrogens and ACE inhibitors and both surgery and cated on HAE triggers, including medications such as estrogens and ACE inhibitors and both surgery and

Discharge Instructions. When discharged from the ED, patients should have ready access to at least one specific modality to treat recurrent symptoms. In the case of HAE, this should include a targeted on-demand therapy.52,62 For all others, and for suspected HAE where no targeted therapy is available for self-administration, they should be discharged with epinephrine until seen by an angioedema specialist who can confirm their diagnosis and appropriate therapeutic intervention. HAE patients on C1-INH or ecallantide are required to have epinephrine on hand in the event of an allergic reaction to these agents. The patient and any available friends or family should receive training for self-administration of targeted therapies in case the patient cannot self-administer during an attack. For patients with known HAE who have on-demand targeted therapy available to them already, refresher training on self-administration of their rescue medication may be needed. Most HAE specialists advocate for self-therapy to help ensure early treatment leading to shorter duration and less severe attacks, which may result in a reduction in absenteeism and morbidity and even potential mortality. The patient should be told to return to the ED, their specialist or their primary care provider if symptoms persist or worsen despite therapy.52,62 Emphasis should be placed on the necessity for patients with upper airway swelling to self-treat without delay and present to the ED for observation since not all cases respond to therapy. Patients with ACE inhibitor-induced angioedema should be told to discontinue their ACE inhibitor. An alternative agent should be discussed with the patient’s primary care physician, if possible. Otherwise, follow-up with a primary care physician to start a new antihypertensive or starting a substitute agent at the discretion of the EP should be performed. Although a modest risk of recurrent angioedema may exist in patients with ACE inhibitor angioedema switched to a calcium channel blocker or an angiotensin receptor blocker, most patients can safely use these agents without recurrent angioedema.65,66

REMAINING CONTROVERSIES

As the parameter was developed, several areas were identified that require further investigation, including:
1. The use of novel pharmaceutical agents (C1-INH, kallikrein inhibitor, or bradykinin receptor antagonist) in patients with ACE inhibitor-induced angioedema or HAE with normal C1-INH.
2. The use of novel pharmaceutical agents (C1-INH, kallikrein inhibitor, or bradykinin receptor antagonist) in patients whose poor response to conventional therapy suggests they have non-HAE non-histamine-mediated angioedema that could be bradykinin-mediated.
3. A validated clinical decision algorithm to identify patients who require nasopharyngoscopy.
4. The use of other modalities to assess the airway in patients with angioedema of the head and neck due to the potential unavailability of nasopharyngoscopy.
5. A point-of-care or laboratory test that can be used to rapidly differentiate bradykinin-mediated angioedema from other forms of angioedema.
6. Comparative effectiveness studies to guide disposition decision-making and follow-up.
7. Head-to-head comparisons of available therapies to determine the most effective intervention for emergency care of the patient with ACE inhibitor-induced angioedema or HAE.

References

5. Lin RY, Anderson AS, Shah SN, Nurruzzaman F. Increasing anaphylaxis hospitalizations in the first 2
10. Craig T, Ayg...